In this article, we will discuss: 11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate. Numerous quickly expanding businesses are arising in the genomics industry as a result of technological advancements that significantly reduce the cost, accuracy, and time required to map a human being’s entire genome. Investors in innovation, like Cathie Wood of Ark Investment Management, believe that these developments are bringing about a “Genomic Revolution.”
The 32nd Plant and Animal Genomics Conference, held in San Diego from January 10-15, 2025, brought attention to how quickly agricultural genomics technology is developing. One noteworthy finding was the dramatic drop in sequencing costs. What took the original Human Genome Project 13 years and $3 billion can now be performed for less than $200 in a matter of days, with new platforms promising $100 per human genome.
These developments are opening up practical research and development in a variety of crops, such as pomegranates and wheat, with a spotlight on yield improvement and climate adaptation. Breeding cycles are being accelerated, especially for perennial crops, by methods like transgenics, genome editing, and marker-assisted breeding. The global effect is nonetheless constrained by regulatory complexity, particularly by uneven policies between regions such as the EU.
With that said, here are the 11 Best Genomics Stocks to Buy According to Hedge Funds.
A laboratory technician using high tech equipment to sequence cancer genomics.
Methodology
For this article, we sifted through Genomics online rankings to form an initial list of the 20 Best Genomics Stocks. From the resultant dataset, we chose 11 stocks with the highest number of hedge fund investors, using Insider Monkey’s database of 1000 hedge funds in Q1 2025 to gauge hedge fund sentiment for stocks. We have used the stock’s revenue growth year-over-year as a tie-breaker in case two or more stocks have the same number of hedge funds invested.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11. Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Number of Hedge Fund Holders: 29
Intellia Therapeutics, Inc. (NASDAQ:NTLA) presented encouraging three-year follow-up data from their Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the EAACI Congress 2025.
All 10 patients were free of attacks and treatment for a median of 23 months after receiving a single dose of lonvo-z, which led to a 98% mean reduction in monthly HAE attacks. Positive safety results were maintained across all treatment dosages. The current Phase 3 HAELO trial has a majority of U.S. enrollment and has completed screening ahead of schedule. Intellia Therapeutics, Inc. (NASDAQ:NTLA) plans to launch in 2027 after submitting a BLA in 2026.
Lonvo-z (NTLA-2002) is an experimental in vivo CRISPR-based gene editing therapy that targets the KLKB1 gene to prevent HAE attacks. The FDA has designated it as an Orphan Drug and RMAT, while the EMA has designated it as PRIME, among other regulatory classifications.
Administered intravenously at doses ranging from 25 to 75 mg, the therapy demonstrated dose-dependent kallikrein protein decrease and long-term efficacy, with no major treatment-related side effects recorded. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the Best Genomics Stocks.
10. Twist Bioscience Corporation (NASDAQ:TWST)
Number of Hedge Fund Holders: 30
Revenue growth (YoY): 27.69%
Twist Bioscience Corporation (NASDAQ:TWST) and Element Biosciences have expanded their relationship to produce end-to-end Next Generation Sequencing (NGS) solutions.
Twist Bioscience Corporation (NASDAQ:TWST)’s library prep and target enrichment workflows are now integrated with Element’s AVITI™ devices and Trinity™ flowcells. Twist will be the only supplier of the new Trinity kits for the AVITI platform as a result of the deal. Both businesses will collaborate on commercial efforts to increase customer access to high-performance NGS technologies.
The expanded relationship builds on past success, including Twist Bioscience Corporation (NASDAQ:TWST)’s Trinity solution for one-hour quick hybridization. The partnership will improve workflows for agbio, genomics, and clinical research by streamlining hybrid capture both off and on sequencers, according to Twist CEO Emily Leproust.
Element Biosciences CEO Molly He highlighted that the combination of Twist Bioscience Corporation (NASDAQ:TWST)’s prep capabilities and Trinity’s focused sequencing is essential to advancing science. The partnership will provide researchers with platform flexibility, uniformity, and quality by extending NGS capabilities beyond exome sequencing. It is ranked tenth on our list of the Best Genomics Stocks.